Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TEMPO: trazodone dose-finding before psilocybin in treatment-resistant depression
2025-523346-27-00Phase 2Authorised
- Sponsor
- Università degli Studi Gabriele d'Annunzio Chieti e Pescara
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trazodone and psilocybin in treatment-resistant depression (TRD) and major depressive disorder (MDD), sponsored by Università degli Studi Gabriele d'Annunzio Chieti e Pescara. Primary endpoint: Safety and tolerability of trazodone administered prior to psilocybin. Planned start Aug 2026; status: authorised.
02
Drugs
trazodonepsilocybin
03
Conditions
treatment-resistant depression (TRD)major depressive disorder (MDD)
Beyond the preview
Go deeper on 2025-523346-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523346-27-00.